Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 50458-0640
Overview of the Drug
NDC 50458-0640 corresponds to Caplacizumab (brand name Cablivi), a prescription medication approved by the FDA in February 2019. It is indicated for acquired thrombotic thrombocytopenic purpura (aTTP), a rare hematologic disorder characterized by small blood clots forming in small blood vessels throughout the body.
Market Adoption and Competitive Landscape
Market Size:
The aTTP market primarily comprises adult patients, estimated at fewer than 500 cases annually in the U.S. (per National Organization for Rare Disorders). The rarity of the disorder constrains total market volume, focusing deployment predominantly in specialized hospitals and hematology centers.
Key Competitors:
Prior to Caplacizumab approval, treatment relied mainly on plasma exchange and immunosuppressants such as corticosteroids and rituximab. Caplacizumab offers a targeted mechanism, leading to faster platelet normalization.
Reimbursement and Pricing:
Medicare and private insurers have adopted coverage strategies aligning with high-cost specialty drugs. The drug’s novel mechanism and clinical benefits justify premium pricing.
Price Analysis
Current List Price:
Per available pricing data, the wholesale acquisition cost (WAC) for a single treatment course of Caplacizumab approximates $12,500 per dose, with the typical course involving multiple doses over 4-5 days.
Cost per Treatment Course:
Based on dosing regimens—assuming an average of 10 doses—the total cost ranges between $125,000 and $150,000.
Reimbursement Trends:
CMS reimbursement structures and private payer policies generally reimburse at or near WAC, with variations depending on geographic and contractual factors.
Market Penetration and Revenue Projections
Historical Sales Data:
Since launch, Caplacizumab sales have grown slowly due to its niche indication. Estimated U.S. revenue in 2022 was approximately $25 million, with European markets contributing an additional $10-15 million.
Growth Drivers:
- Increasing recognition and diagnosis of aTTP.
- Expansion of approved indications (e.g., pediatric use under research).
- Uptake in hospitals and specialty clinics.
Factors Limiting Growth:
- Price sensitivity among payers for rare disease drugs.
- Competition from off-label use of existing therapies.
- Small patient population constrains total revenue potential.
Future Price and Revenue Projections:
Assuming continued market penetration and no major price reductions:
| Year |
Estimated U.S. Revenue |
Assumed Price per Course |
Key Drivers |
| 2023 |
$30 million |
$125,000 - $150,000 |
Increased diagnosis, wider adoption |
| 2024 |
$50 million |
Same |
Expanded clinical acceptance, payer coverage |
| 2025 |
$75 million |
Slight decrease (10%) |
Price negotiations, global expansion |
Regulatory and Policy Environment Impact
- Pricing regulations: CMS initiatives aim to control high-cost treatments via programs like the Medicare Drug Price Negotiation Act.
- Orphan drug status: Maintains market exclusivity until at least 2030, shielding against biosimilar competition.
- Global access: Pricing varies worldwide, with developed markets paying premium prices and emerging markets facing affordability barriers.
Risks and Opportunities
Risks:
- Potential emergence of biosimilars after patent expiry.
- Payer resistance to high upfront costs.
- Emergence of alternative therapies or improved diagnostics reducing demand.
Opportunities:
- Cost savings through improved patient outcomes reducing hospitalization.
- Combining Caplacizumab with other agents in broader thrombotic disorders.
- Broader indication approvals increasing patient target base.
Key Takeaways
- Caplacizumab maintains a high-cost niche position amid limited competition.
- Market growth depends on improved diagnosis rates and clinical adoption.
- Price projections suggest stable or slight decline, constrained by payer negotiations.
- Revenue growth will likely plateau post-2025 without new indications.
FAQs
1. How does the price of NDC 50458-0640 compare to other rare disease drugs?
It aligns with the high-end pricing typical for biologics treating rare conditions, often exceeding $100,000 per treatment course.
2. What factors most influence pricing strategies for this drug?
Reimbursement policies, clinical efficacy, competition, and manufacturing costs.
3. Is the drug price expected to decrease in the near future?
Potentially, as negotiations with payers and market dynamics evolve, but significant reductions are unlikely within the current patent period.
4. Could biosimilars impact the market for NDC 50458-0640?
Yes, biosimilars could enter post-patent expiration, potentially reducing prices and market share.
5. What is the revenue outlook for Caplacizumab globally?
Primarily driven by the U.S. and Europe, with minimal contribution from emerging markets until pricing and access barriers are addressed.
Sources:
- FDA approval documents for Caplacizumab (Cablivi).
- IQVIA sales data and forecasts.
- Medicare formulary coverage guidelines.
- European Medicines Agency (EMA) approval summaries.
- Industry reports on rare disease drug pricing and market dynamics.
